Preoperative Window of Opportunity Study with Giredestrant (GDC-9545) or Tamoxifen in Premenopausal Women with ERHER2-] & KI6710 Early Breast Cancer

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Medica Scientia Innovation Research S.L.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

19 Jul 2023 → 30 Jan 2025

Decision date (initial)

2023-06-09

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

External identifiers

EU CT number

2023-503565-36-00

ClinicalTrials.gov

NCT05659563

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Therapy

To assess changes in tumor cell proliferation as measured by Ki67 expression between baseline and post-treatment tumor biopsy samples by central assessment in patients with centrally confirmed Ki67≥10% (Arm A vs Arm B).

Secondary objectives 6

1. To measure complete cell cycle arrest (CCCA) in all arms, defined by Ki67≤2.7% in post-treatment sample.
2. To analyze changes in ER and PgR levels, and molecular profiling using HTG.
3. To evaluate toxicity according to National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI- CTCAE) v.5.0.
4. To analyze differences in blood biomarkers performing a plasma endocrine panel with samples pre- and post-therapy.
5. To analyze the expression of ER and PgR in samples pre- and post-therapy.
6. Other exploratory studies to be determined.

Conditions and MedDRA coding

ER[+]/HER2[-] & Ki67≥10% early breast cancer (EBC)

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 10

1. Signed Informed Consent Form (ICF) prior to beginning specific protocol procedures.
2. Age ≥18 years at time of signing ICF.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Women with a well-determined premenopausal status as indicated in the protocol.
5. Histologically confirmed invasive breast carcinoma, with all the following characteristics: a. Documented ER[+] tumor in accordance with American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (Allison et al., 2020), assessed locally and defined as ≥1% of tumor cells stained positive. b. Documented HER2[-] tumor in accordance with 2018 ASCO/CAP guidelines (Wolff et al., 2018), assessed locally at baseline. Note: Diagnostic biopsy taken no more than 8 weeks prior to initiation of study treatment can be used as baseline. c. Ki67 score ≥10% analyzed locally and centrally confirmed (Nielsen et al., 2021). Note: Ki67 will be analyzed locally at the time of inclusion. Patients with basal Ki67≥20% will be assessed locally and centrally confirmed retrospectively and patients with 10-19% will be assessed centrally before inclusion. d. Tumor size must be ≥1.0 cm in longest diameter by ultrasound as per Response Evaluation Criteria in solid Tumors (RECIST) criteria. Note: Patients with multifocal or multicentric breast cancer with at least one tumor lesion ≥1.0 cm in the longest diameter by ultrasound (reference lesion) are also eligible if the two largest tumor lesions have been histologically confirmed in the clinical evaluation and meet pathologic criteria for ER positivity and HER2 negativity.
6. Willingness to provide a primary tumor tissue and blood sample obtained at baseline as well as a post-treatment tumor tissue and a blood sample (breast biopsy or breast surgery).
7. Patient has adequate bone marrow, liver, and renal function: • Hematological: absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1500/mL), platelet count ≥ 100.0 x109/L, and hemoglobin ≥ 9 g/dL (≥ 90g/L). Note: The blood counts are to meet the specified criteria without transfusion or growth factor support, unless it is clear that the bone marrow function is adequate and that any aberration has a clear and correctable cause, and the correction undertaken. • Hepatic: total serum bilirubin ≤ 1.5’ institutional upper limit of normal (ULN) (patients with known Gilbert’s syndrome: ≤ 3’ ULN); alkaline phosphatase (ALP) ≤ 2.5 times ULN; aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3’ times ULN. • Coagulation: The international normalized ratio (INR) < 1.5’ ULN and partial thromboplastin time (PTT or aPTT) < 1.5’ ULN (except for patients receiving anticoagulation therapy). For patients receiving warfarin, a stable INR between 2 and 3 is required. For patients receiving heparin, PTT (or aPTT) between 1.5 and 2.5’ ULN (or patient value before starting heparin treatment) is required. If anticoagulation therapy is required for a prosthetic heart valve, stable INR between 2.5 and 3.5 is permitted. • Renal: creatinine clearance ≥ 60 mL/min for patients with creatinine levels above institutional normal.
8. Negative serum pregnancy test result within 7 days prior to initiation of study treatment, and a negative urine pregnancy test within 24 hours prior to study treatment initiation. Note: Premenopausal women age ≥18 years with premenopausal status defined as: estradiol (E2) in the premenopausal range (according to institution parameters) or patient has been menstruating regularly during the 6 months prior to randomization and has not used any form of hormonal contraception or any other hormonal treatments during this time. Women must remain abstinent and truly abstain from sexual activity (refrains from heterosexual intercourse) or use of locally recognized adequate methods of contraception (described as that with a failure rate <1%) during the length of the study, and to continue its use for 10 days after the last dose of study treatment (for patients taking giredestrant) or 9 months following cessation of therapy (for patients in the tamoxifen arm). They must, as well, agree to refrain from donating eggs during the same period. Examples of non-hormonal contraceptive method with a failure rate of <1% per year (e.g. bilateral tubal ligation, male sterilization and copper intrauterine devices). The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.
9. Patients must be accessible for treatment and follow-up.
10. Participants who are able and willing to swallow, retain, and absorb oral medication.

Exclusion criteria 20

1. Progesterone receptor (PgR)[+] and ER[-] patients.
2. cT4 and/or cN2/3 and/or bilateral BC.
3. Patients who have history of any prior (ipsilateral and/or contralateral) invasive breast cancer or Ductal carcinoma in situ (DCIS). Participants with a history of contralateral DCIS treated by only local regional therapy at any time may be eligible.
4. Evidence of metastatic disease.
5. Previous systemic or local treatment for the primary breast cancer currently under investigation.
6. History of any prior treatment with chemotherapy drugs, aromatase inhibitors (AIs), tamoxifen, selective estrogen receptor down regulator, or cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i).
7. Major surgery within 4 weeks prior to randomization.
8. Any invasive malignancy diagnosed within the previous 5 years prior to screening in this study (other than basal cell carcinoma, cervical carcinoma in situ or contralateral DCIS).
9. Known issues with swallowing oral medication, or inability or unwillingness to swallow oral medication.
10. Participants who have a known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including hepatitis (e.g., hepatitis B virus [HBV] or hepatitis C virus [HCV]), current alcohol abuse, cirrhosis, or positive test for viral hepatitis, as defined in the protocol.
11. Active cardiac disease or history of cardiac dysfunction including any of the following: • History or presence of symptomatic bradycardia or sick sinus syndrome. • Resting heart rate <50 bpm at screening. • History of angina pectoris, symptomatic pericarditis, myocardial infarction, or any cardiac arrhythmias (e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality) within 12 months prior to study entry. • History of documented congestive heart failure (New York Heart Association Class II-IV) or cardiomyopathy. • QT interval corrected through use of Fridericia’s formula (QTcF) >470 ms by at least three ECGs >30 minutes apart. • History of long or short QT syndrome, Brugada syndrome or known history of corrected QT interval prolongation, or torsades de pointes. • History or presence of an abnormal ECG that is clinically significant in the investigator’s opinion.• History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy cardiomyopathy, infiltrative cardiomyopathy, moderate-to-severe valve disease),, coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of long QT syndrome.
12. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study.
13. Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization.
14. Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or major upper gastrointestinal surgery including gastric resection.
15. Participants who have a known allergy or hypersensitivity to any of the study drugs or any of their excipients
16. Participants who are pregnant or breastfeeding or intending to become pregnant during the study or within 10 days after the final dose of giredestrant (GDC-9545), or within 9 months after the final dose of tamoxifen. Note: Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment and a negative urine pregnancy test within 24 hours prior to study treatment initiation.
17. Patients with renal dysfunction who require dialysis.
18. Participants who have had a serious infection requiring oral or IV antibiotics within 14 days prior to screening or other clinically significant infection (e.g., COVID-19) within 14 days prior to screening. Note: Participants who have fully recovered from serious or clinically significant infections at least 14 days prior to screening are eligible. If a participant exhibits signs or symptoms of potential COVID-19 infection and there is a reasonable suspicion of exposure, investigators are to follow the American Society of Clinical Oncology 2020 guidelines or institutional guidelines on testing.
19. Participants who have had a major surgical procedure unrelated to breast cancer within 28 days prior to randomization.
20. Participants who are unable or unwilling to comply with the requirements of the protocol in the opinion of the investigator.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Changes in tumor cell proliferation as measured by Ki67 expression between baseline and post-treatment tumor biopsy samples by central assessment in patients with centrally confirmed Ki67 ≥10% (Arm A vs Arm B).

Secondary endpoints 6

1. CCCA in all arms, defined as the percentage of participants with centrally assessed Ki67 scores ≤2.7% stained nuclei upon treatment (post-treatment sample).
2. Changes in markers (such as ER and PgR levels) and molecular profiling using HTG (PAM-like molecular test).
3. Incidence and severity of adverse events (AEs), with severity determined in accordance with NCI-CTCAE v.5.0.
4. Plasma endocrine panel performed pre- and post-therapy.
5. Expression of ER and PgR in samples pre- and post-therapy.
6. Other exploratory studies to be determined.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Comparator 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Medica Scientia Innovation Research S.L.

Sponsor organisation

Medica Scientia Innovation Research S.L.

Address

Rambla De Catalunya 2 Planta 2 D

City

Barcelona

Postcode

08007

Country

Spain

Scientific contact point

Organisation

Medica Scientia Innovation Research S.L.

Contact name

Alicia Sanz

Public contact point

Organisation

Medica Scientia Innovation Research S.L.

Contact name

Alicia Sanz

Third parties 3

Locations

2 EU/EEA countries · 21 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Summary of results Art. 37(4) CTR

Layperson summary Annex V

Documents 10 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

6 submissions — initial application plus substantial / non-substantial modifications